Sorafenib is a widely used multi-kinase inhibitor that targets both the RAF/MEK/ERK pathway and receptor tyrosine kinases, thereby further inhibits tumor growth and angiogenesis in several tumors17. This evidence concerns the gene NTRK1 and neoplasm.